What You Ought to Know:
– Scopio Labs, developer of Full-Discipline Cell Morphology imaging and evaluation platform, introduced in the present day the revealing of its groundbreaking Full Blood Morphology (CBM®) analyzer. CBM will carry unprecedented scale, effectivity and standardization to hematology via autonomous morphology evaluation and reporting, one of many final remaining handbook processes in diagnostics.
– To expedite the go-to-market of CBM®, Viola Progress has joined as a brand new investor with a $10 million extension to Scopio’s Collection D funding, bringing the overall to $52 million.
Closing the Automation Hole in Hematology with CBM® and Scopio’s Full-Discipline Expertise
Addressing a Essential Bottleneck in Peripheral Blood Smear Assessment
Regardless of many years of automation in Full Blood Depend (CBC) testing, the peripheral blood smear (PBS) evaluate course of stays labor-intensive, inconsistent, and a big bottleneck in scientific workflows. This problem is compounded by world workforce shortages, lengthy technologist coaching cycles, and rising diagnostic demand—all contributing to delayed turnaround instances and compromised scalability in affected person care. Whereas automation has streamlined many areas of the lab, PBS evaluate nonetheless depends on human interpretation, introducing variability and inefficiency that fashionable laboratories can now not afford.
Scopio Labs’ CBM®: A New Period of Automated Morphology
Scopio Labs’ CBM® platform, powered by its proprietary Full-Discipline imaging know-how and AI-driven evaluation, is designed to autonomously course of PBS evaluations, analyzing 10x extra cells than conventional strategies. The result’s a standardized, scalable, and clinically strong workflow that reduces dependency on handbook evaluate. Laboratories already utilizing Scopio’s CE-marked and FDA-cleared digital platforms for PBS and bone marrow aspirate evaluation are seeing marked enhancements in effectivity and readiness for CBM® integration.
Based on Itai Hayut, CEO and Co-founder of Scopio Labs, “Our imaginative and prescient is to be the primary to shut the automation hole in hematology by creating a totally built-in and automatic hematology course of from CBC to remaining end result. This isn’t only a small step ahead—it’s a paradigm shift that would redefine hematology workflows and economics.” Past automating present practices, CBM® can be positioned to unlock new capabilities in morphology-based biomarkers and diagnostic panels, facilitating early illness detection and monitoring instantly from blood samples.
